Accelerating drug development: Methodology to support first-in-man pharmacokinetic studies by the use of drug candidate microdosing

Drug Development Research

Volumn 68, Issue 1, 2007, Pages 14-22

  McLean, Matthew A ^a   Tam, Chi Yan J ^b   Baratta, Michael T ^c   Holliman, Christopher L ^c   Ings, Robert M ^d   Galluppi, Gerald R ^e,f  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c PFIZER INC   (United States)

^d ROCHE BIOSCIENCE   (United States)

^e Seventh Wave Laboratories   (United States)

^f Seventh Wave Laboratories   (United States)

Author keywords

Drug development; LC MS; Microdosing; Pharmacokinetics

Indexed keywords

CARBOXYLIC ACID DERIVATIVE;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUSTRY; FEASIBILITY STUDY; ISOTOPE LABELING; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; NONLINEAR SYSTEM; SENSITIVITY AND SPECIFICITY; SOLID PHASE MICROEXTRACTION;

EID: 34249939529     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20160     Document Type: Article

References (11)

1. Aiello M, Plomley J, Deagon N, Caraiman D. 2005. Increased sensitivity for the quantitation of resolved epimers of budesonide extracted from rat plasma utilizing an API 5000 LC-MS/MS system. Proceedings of the 53rd ASMS Conference on Mass Spectrometry and Allied Topics, San Antonio, TX. June 5-9, 2005.
2. Balani S, Nagaraja N, Qian M, Costa A, Daniels J, Yang H, Shimoga P, Wu J, Gan L, Lee F, Miwa G. 2006. Evaluation of microdosing to assess pharmacokinetic linearity in rats using LC/MS/MS. Drug Metab Dispos 34:384-388.
3. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP). 2004. Position paper on non-clinical safety studies to support clinical trials with a single microdose. CPMP, SWP, 2599, 02, Rev 1, London. 23 June 2004.
4. Garner R. 2005. Less is more: the human microdosing concept. Drug Discov Today 10:449-451.
5. Lappin G, Garner R. 2003. Big physics, small doses: The use of AMS and PET in human microdosing of development drugs. Nature Rev Drug Discov 2:233-240.
6. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Ooterhuis B, Drijfthout W, Rowland M, Garner R. 2006. Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs. Clin Pharmacol Ther 80:203-215.
7. Plomley J, Deagon N, Xhong F, Caraiman D. 2005. Increased sensitivity utilizing an API 5000 coupled to reduced sample volumes for the analysis of mitoxantrone extracted from neonatal plasma. Proceedings of the 53rd ASMS Conference on Mass Spectrometry and Allied Topics, San Antonio, TX. June 5-9, 2005.
8. Sandhu P, Vogel J, Rose M, Ubick E, Brunner J, Wallace M, Adelsberger J, Baker M, Henderson P, Pearson P, Baillie T. 2004. Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab Dispos 32:1254-1259.
9. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2005. Guidance for industry, investigators, and reviewers: Exploratory IND studies draft guidance. 6384dft.doc. 07 April 2005.
10. Wilding I. 2005. Supplement 19: Use of human microdosing studies to improve the pharmacokinetic/bioavailability (PK/BA) quality of new drug candidates: A practical guide. In: Luscombe D, Stonier P, editors. Clinical research manual, Haslemere, England: Euromed Communications. p S19.1-S19.10.
11. Wilding I, Bell J. 2005. Improved early clinical development through human microdosing studies. Drug Discov Today 10: 890-894.